Tenax Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $66.6M
- Price
- $1.78
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.32%
- Volume
- 4.1M
About
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have successfully completed Phase II clinical trials. These compounds are being developed to manage pulmonary hypertension, particularly that linked to heart failure with preserved ejection fraction (HFpEF), as well as other forms of associated pulmonary hypertension. Additionally, the company is progressing TNX-201 (imatinib), a tyrosine kinase inhibitor, designed to treat pulmonary arterial hypertension. Founded in 1967, the organization was initially known as Oxygen Biotherapeutics, Inc. until its rebranding to Tenax Therapeutics, Inc. in September 2014. The company maintains its corporate headquarters in Morrisville, North Carolina.
Quick stats
Shares outstanding37.4M
Computed float3.3M
Float / shares8.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000034956
Websitehttps://www.tenaxthera.com
AI Summary
AI-generated1/29
minorneutrallegal litigation
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP announced an investigation into Tenax Therapeutics regarding potential violations of federal securities laws.
The investigation focuses on whether the company issued misleading statements related to its Phase 3 LEVEL trial of TNX-103, which failed to meet primary and secondary endpoints.
Following the trial news, shares of Tenax fell by almost 90%; the firm is soliciting shareholders who suffered losses to discuss their rights.